1. Red. Kostowski W., Herman Z., Farmakologia. Podstawy farmakoterapii. Podręcznik dla studentów medycyny i lekarzy. Tom 1 i 2. Warszawa: Wydawnictwo Lekarskie PZWL, 2013.

2. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision., J Allergy Clin Immunol. 2010 Sep;126(3):466-76.

3. Grant JA., Molecular pharmacology of second-generation antihistamines., Allergy Asthma Proc. 2000 May-Jun;21(3):135-40.

4. CHPL Aerius.

5. CHPL Telfast Sanofi.

6. CHPL Clatra.

7. CHPL Rupafin.

8. Molimard M1, Diquet B, Benedetti MS., Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans., Fundam Clin Pharmacol. 2004 Aug;18(4):399-411.

9. M. J. Hanley, P. Cancalon, W. W. Widmer, and D. J. Greenblatt, “The effect of grapefruit juice on drug disposition,” Expert Opinion on

Drug Metabolism and Toxicology, vol. 7, no. 3, pp. 267–286, 2011.

10. Farré M., Pérez-Mañá C, Papaseit E, Menoyo E, Pérez M, Martin S, Bullich S, Rojas S, Herance JR, Trampal C, Labeaga L, Valiente R., Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers., Br J Clin Pharmacol. 2014 Nov;78(5):970-80.

11. Wolthers OD., Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria., Biomed Res Int. 2013;2013:626837.

12. Carter NJ., Bilastine: in allergic rhinitis and urticaria., Drugs. 2012 Jun 18;72(9):1257-69.

13. Jáuregui I1, Ferrer M, Bartra J, del Cuvillo A, Dávila I, Montoro J, Mullol J, Sastre J, Valero A., Bilastine for the treatment of urticaria., Expert Opin Pharmacother. 2013 Aug;14(11):1537-44.

14. Lucero ML, Peither A, Ledo F., Bilastine: an environmental risk assessment., Drug Chem Toxicol. 2015 Jan 22:1-9.

15. Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, Roupe K, Blanco N, Wheeler W., Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis., J Clin Pharmacol. 2012 Jun;52(6):893-903.

16. Xiong Y, Yuan Z, Yang J, Xia C, Li X, Huang S, Zhang H, Liu M., CYP3A5* 3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers., Eur J Drug Metab Pharmacokinet. 2014 Nov 27.

17. Poluzzi E, Raschi E, Godman B, Koci A, Moretti U, Kalaba M, Wettermark B, Sturkenboom M, De Ponti F., Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe., PLoS One. 2015 Mar 18;10(3):e0119551.

18. Elisabetta Poluzzi, Emanuel Raschi, Brian Godman, Ariola Koci, Ugo Moretti, Marija Kalaba, Bjorn Wettermark, Miriam Sturkenboom, and Fabrizio De Ponti, Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe, PLoS One. 2015; 10(3): e0119551.

19. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT., BSACI guideline for the management of chronic urticaria and angioedema., Clin Exp Allergy. 2015 Mar;45(3):547-65.

20. Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA., Antihistamines and birth defects: a systematic review of the literature., Expert Opin Drug Saf. 2014 Dec;13(12):1667-98.

21. Qian Li, MS, Allen A. Mitchell, MD, Martha M. Werler, ScD, Wai- Ping Yau, PhD, and Sonia Hernández-Díaz, MD, DrPH, Antihistamine Use in Early Pregnancy and Risk of Birth Defects, J Allergy Clin Immunol Pract. 2013 Nov-Dec; 1(6): 666–74.e1.

22. Li Q, Mitchell AA, Werler MM, Yau WP, Hernández-Díaz S., Assessment of antihistamine use in early pregnancy and birth defects., J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):666-74.e1.

23. N. Jauregizar, L. D. L. Fuente, M. L. Lucero, A. Sologuren, N. Leal, and M. Rodríguez, “Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H 1) Effect of Bilastine,” Clinical Pharmacokinetics, vol. 48, no. 8, pp. 543–554, 2009.

24. G. M. Walsh, L. Annunziato, N. Frossard et al., “New insights into the second generation antihistamines,” Drugs, vol. 61, no. 2, pp. 207–236, 2001.

25. F. Horak, P. Zieglmayer, R. Zieglmayer, and P. Lemell, “The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen- induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber,” Inflammation Research, vol. 59, no. 5, pp. 391–398, 2010.

26. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group., Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients., Allergy. 2009 Jan;64(1):158-65.

27. Wilson AM1, Haggart K, Sims EJ, Lipworth BJ., Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis., Clin Exp Allergy. 2002 Oct;32(10):1504-9.